The introduction of the diagnostic-therapeutic approach based on Systems Medicine into the medical scenario has allowed us to deeper investigate into the concept of the human organism as a set of interconnected networks. This wide vision, in addition to shedding new light on the interpretation of pathological manifestations, allows us to set up new therapeutic strategies based on the management of alterations in the networks identified as involved in the onset and progression of the disease. The tool that, to date, can allow to set up network regulation treatments is Low Dose Medicine, a therapeutic approach based on low-dose pharmacology. The use of low doses signaling molecules is the physiologically most appropriate option for the management of network alterations. In the pediatric field, numerous experiences have confirmed the validity of this approach. A preclinical study and a Delphi Consensus have provided clear evidence on the action mechanism and clinical application of a low-dose medication (Citomix®) for the prevention and early treatment of Recurrent Respiratory Infections. The consensus was based on preclinical data and was aimed to collect clinical experiences with Citomix® about the biological capacity to modulate the immune response in the presence of infectious agents. The cornerstone of the consensus was the validation of the use of Citomix® as an option for the prevention and early add-on treatment of RRIs; the positive result which emerge from the vote of the statements constituting the consensus confirmed the validity of the investigated option.
| Published in | American Journal of Pediatrics (Volume 10, Issue 4) |
| DOI | 10.11648/j.ajp.20241004.24 |
| Page(s) | 244-251 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Low Dose Medicine, Low Dose Pharmacology, Recurrent Respiratory Infections, Citomix, Immunomodulation, Delphi Consensus
| [1] | Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011; 12(1): 56-68. |
| [2] | Dai X, Shen L. Advances and Trends in Omics Technology Development. Front Med (Lausanne). 2022; 9: 911861. |
| [3] | Conte F, Fiscon G, Licursi V. A paradigm shift in medicine: A comprehensive review of network-based approaches. Biochim Biophys Acta Gene Regul Mech. 2020; 1863(6): 194416. |
| [4] | Ader R, Cohen N, Felten DL. Brain, behavior, and immunity. Brain Behav Immun. 1987; 1(1): 1-6. |
| [5] | Ader R, Felten D, Cohen N. Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol. 1990; 30: 561-602. |
| [6] | Ader R, Cohen N. Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol. 1993; 44: 53-85. |
| [7] | Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 1995; 345(8942): 99-103. |
| [8] | Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012; 37(1): 137-62. |
| [9] | Bernasconi S. Low Dose Medicine: theoretical background and scientific evidence. Ital J Pediatr. 2018; 44(1): 23. |
| [10] | Ngoc PL, Gold DR, Tzianabos AO. Curr Opin Allergy Clin Immunol. 2005; 5(2): 161-6. |
| [11] | Lourenço EV, La Cava A. Cytokines in systemic lupus erythematosus. Curr Mol Med. 2009; 9(3): 242-54. |
| [12] | Vandenberg LN, Colborn T, Hayes TB. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev. 2012; 33(3): 378-455. |
| [13] | Biancotto A, Wank A, Perl S. Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2013; 8(12): e76091. |
| [14] | Reeves R, Leonard WJ, Nissen MS. Binding of HMG-I(Y) imparts architectural specificity to a positioned nucleosome on the promoter of the human interleukin-2 receptor alpha gene. Mol Cell Biol. 2000; 20(13): 4666-79. |
| [15] | Ishihara K, Hirano T. Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta. 2002; 1592(3): 281-96. |
| [16] | Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010; 125(2 Suppl 2): S53-72. |
| [17] | Méndez-Samperio P, Badillo-Flores A, Nuñez-Vazquez A. Interleukin-4 inhibits secretion of interleukin-1beta in the response of human cells to mycobacterial heat shock proteins. Clin Diagn Lab Immunol. 1997; 4(6): 665-70. |
| [18] | Cooke A. Th17 cells in inflammatory conditions. Rev Diabet Stud. 2006; 3(2): 72-5. |
| [19] | Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol. 2007; 19(6): 652-7. |
| [20] | Gariboldi S, Palazzo M, Zanobbio L, Dusio GF, Mauro V, Solimene U, Cardani D, Mantovani M, Rumio C. Low dose oral administration of cytokines for treatment of allergic asthma. Pulm Pharmacol Ther. 2009; 22(6): 497-510. |
| [21] | D’Amico L, Ruffini E, Ferracini R. Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non Small Cell Lung Cancer Patients. Journal of Cancer Therapy 2012; 3: 337-342. |
| [22] | Cardani D, Dusio GF, Luchini P. Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation. Gastroenterology Res. 2013; 6(4): 124-133. |
| [23] | Radice E, Miranda V, Bellone G. Low-doses of sequential-kinetic-activated interferon-γ enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study. Int Immunopharmacol. 2014; 19(1): 66-73. |
| [24] | Roberti ML, Ricottini L, Capponi A. Immunomodulating treatment with low dose interleukin-4, interleukin-10 and interleukin-11 in psoriasis vulgaris. J Biol Regul Homeost Agents. 2014; 28(1): 133-9. |
| [25] | Luchetti P. Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine. Monocentric retrospective observational study. Minerva Oftalmologica 2014; 56(3-4): 53-61. |
| [26] | Barygina V, Becatti M, Lotti T. Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. J Dermatol Sci. 2015; 79(2): 163-70. |
| [27] | Lotti T, Hercogova J, Wollina U. Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments. J Biol Regul Homeost Agents. 2015; 29(1 Suppl): 53-8. |
| [28] | Radice E, Bellone G, Miranda V. Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. A Preliminary Study. Transl Oncol. 2015; 8(4): 327-38. |
| [29] | Lotti T. Successful combination treatment for psoriasis with phototherapy and low-dose cytokines: A spontaneous, retrospective observational clinical study. Hautarzt. 2015; 66(11): 849-54. German. |
| [30] | Barygina V, Becatti M, Lotti T. Low dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients. J Dermatol Sci. 2016; 83(3): 242-4. |
| [31] | Tessaro I, Modina SC, Franciosi F. Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome. J Ovarian Res. 2015 Oct 6; 8: 64. |
| [32] | Genazzani AD, Despini G, Chierchia E, Benedetti C, Prati A. Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea. Chapter. Frontiers in Gynecological Endocrinology Part of the series ISGE Series pp 69-84. |
| [33] | Mancini F, Milardi D, Carfagna P. Low-dose SKA Progesterone and Interleukin-10 modulate the inflammatory pathway in endometriotic cell lines. Int Immunopharmacol. 2018; 55: 223-230. |
| [34] | Martin-Martin LS, Giovannangeli F, Bizzi E, An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. Drug Des Devel Ther. 2017; 11: 985-994. |
| [35] | Carello R, Ricottini L, Miranda V. Long-term treatment with low-dose medicine in chronic childhood eczema: a double-blind two-stage randomized control trial. Ital J Pediatr. 2017; 43(1): 78. |
| [36] | Tagliacarne SC, Valsecchi C, Benazzo M. Low-dose multicomponent medication modulates humoral and cellular immune response in an ex-vivo study on children subjected to adenoid surgery. Immunol Lett. 2018; 203: 95-101. |
| [37] | Molinari C, Morsanuto V, Ruga S, Notte F, Farghali M, Galla R, Uberti F. The Role of BDNF on Aging-Modulation Markers. Brain Sci. 2020; 10(5): 285. |
| [38] | Chiappini E, Santamaria F, Marseglia GL. Prevention of recurrent respiratory infections: Inter-society Consensus. Ital J Pediatr. 2021; 47(1): 211. |
| [39] | Arrighi A. CITOMIX vs IMMUCYTAL® nella prevenzione e terapia delle Infezioni Respiratorie Acute in età pediatrica – Studio prospettico controllato. La Med Biol 2009; 3: 3-11. |
| [40] | Lombardi Mistura E. – Lymphomyosot ®, Citomix e Omeogriphi ® nella prevenzione delle Infezioni Respiratorie Ricorrenti in Pediatria. La Med. Biol 2015; 1: 15-24. |
| [41] | Agosti M, Arrighi A, Bernasconi S. A low-dose multicomponent medication as a new approach in prevention and early add-on treatment of recurrent respiratory infections in children: a Delphi Consensus. Eur Rev Med Pharmacol Sci. 2024; 28(16): 4156-4169. |
APA Style
Bernasconi, S. (2024). Systems Medicine and the Contribution of Low Dose Pharmacology in Paediatrics. American Journal of Pediatrics, 10(4), 244-251. https://doi.org/10.11648/j.ajp.20241004.24
ACS Style
Bernasconi, S. Systems Medicine and the Contribution of Low Dose Pharmacology in Paediatrics. Am. J. Pediatr. 2024, 10(4), 244-251. doi: 10.11648/j.ajp.20241004.24
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajp.20241004.24,
author = {Sergio Bernasconi},
title = {Systems Medicine and the Contribution of Low Dose Pharmacology in Paediatrics
},
journal = {American Journal of Pediatrics},
volume = {10},
number = {4},
pages = {244-251},
doi = {10.11648/j.ajp.20241004.24},
url = {https://doi.org/10.11648/j.ajp.20241004.24},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20241004.24},
abstract = {The introduction of the diagnostic-therapeutic approach based on Systems Medicine into the medical scenario has allowed us to deeper investigate into the concept of the human organism as a set of interconnected networks. This wide vision, in addition to shedding new light on the interpretation of pathological manifestations, allows us to set up new therapeutic strategies based on the management of alterations in the networks identified as involved in the onset and progression of the disease. The tool that, to date, can allow to set up network regulation treatments is Low Dose Medicine, a therapeutic approach based on low-dose pharmacology. The use of low doses signaling molecules is the physiologically most appropriate option for the management of network alterations. In the pediatric field, numerous experiences have confirmed the validity of this approach. A preclinical study and a Delphi Consensus have provided clear evidence on the action mechanism and clinical application of a low-dose medication (Citomix®) for the prevention and early treatment of Recurrent Respiratory Infections. The consensus was based on preclinical data and was aimed to collect clinical experiences with Citomix® about the biological capacity to modulate the immune response in the presence of infectious agents. The cornerstone of the consensus was the validation of the use of Citomix® as an option for the prevention and early add-on treatment of RRIs; the positive result which emerge from the vote of the statements constituting the consensus confirmed the validity of the investigated option.
},
year = {2024}
}
TY - JOUR T1 - Systems Medicine and the Contribution of Low Dose Pharmacology in Paediatrics AU - Sergio Bernasconi Y1 - 2024/12/31 PY - 2024 N1 - https://doi.org/10.11648/j.ajp.20241004.24 DO - 10.11648/j.ajp.20241004.24 T2 - American Journal of Pediatrics JF - American Journal of Pediatrics JO - American Journal of Pediatrics SP - 244 EP - 251 PB - Science Publishing Group SN - 2472-0909 UR - https://doi.org/10.11648/j.ajp.20241004.24 AB - The introduction of the diagnostic-therapeutic approach based on Systems Medicine into the medical scenario has allowed us to deeper investigate into the concept of the human organism as a set of interconnected networks. This wide vision, in addition to shedding new light on the interpretation of pathological manifestations, allows us to set up new therapeutic strategies based on the management of alterations in the networks identified as involved in the onset and progression of the disease. The tool that, to date, can allow to set up network regulation treatments is Low Dose Medicine, a therapeutic approach based on low-dose pharmacology. The use of low doses signaling molecules is the physiologically most appropriate option for the management of network alterations. In the pediatric field, numerous experiences have confirmed the validity of this approach. A preclinical study and a Delphi Consensus have provided clear evidence on the action mechanism and clinical application of a low-dose medication (Citomix®) for the prevention and early treatment of Recurrent Respiratory Infections. The consensus was based on preclinical data and was aimed to collect clinical experiences with Citomix® about the biological capacity to modulate the immune response in the presence of infectious agents. The cornerstone of the consensus was the validation of the use of Citomix® as an option for the prevention and early add-on treatment of RRIs; the positive result which emerge from the vote of the statements constituting the consensus confirmed the validity of the investigated option. VL - 10 IS - 4 ER -
Secretary of the “Complementary Medicines and Integrated Therapies” Study Group of the Italian, Pediatric Society (SIP – Società Italiana di Pediatria), Parma, Italy
